CL2013003272A1 - Métodos de tratamientos terapéuticos contra células b cd19 positivas a través de la administración del inmunoconjugado hub4-dm4 (sar3419); regimenes de administración; artículos manufacturados que contengan el inmunoconjugado - Google Patents
Métodos de tratamientos terapéuticos contra células b cd19 positivas a través de la administración del inmunoconjugado hub4-dm4 (sar3419); regimenes de administración; artículos manufacturados que contengan el inmunoconjugadoInfo
- Publication number
- CL2013003272A1 CL2013003272A1 CL2013003272A CL2013003272A CL2013003272A1 CL 2013003272 A1 CL2013003272 A1 CL 2013003272A1 CL 2013003272 A CL2013003272 A CL 2013003272A CL 2013003272 A CL2013003272 A CL 2013003272A CL 2013003272 A1 CL2013003272 A1 CL 2013003272A1
- Authority
- CL
- Chile
- Prior art keywords
- immunoconjugate
- administration
- sar3419
- hub4
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11290232A EP2524929A1 (en) | 2011-05-17 | 2011-05-17 | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013003272A1 true CL2013003272A1 (es) | 2014-08-01 |
Family
ID=46085972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013003272A CL2013003272A1 (es) | 2011-05-17 | 2013-11-14 | Métodos de tratamientos terapéuticos contra células b cd19 positivas a través de la administración del inmunoconjugado hub4-dm4 (sar3419); regimenes de administración; artículos manufacturados que contengan el inmunoconjugado |
Country Status (30)
Country | Link |
---|---|
US (2) | US9555126B2 (es) |
EP (2) | EP2524929A1 (es) |
JP (4) | JP6050328B2 (es) |
KR (1) | KR20140043388A (es) |
CN (2) | CN107007840A (es) |
AR (1) | AR086412A1 (es) |
AU (3) | AU2012258254B2 (es) |
BR (1) | BR112013029330A8 (es) |
CA (1) | CA2835738A1 (es) |
CL (1) | CL2013003272A1 (es) |
CO (1) | CO6821893A2 (es) |
CR (1) | CR20130593A (es) |
DO (1) | DOP2013000260A (es) |
EA (1) | EA028574B1 (es) |
EC (1) | ECSP13013084A (es) |
GT (1) | GT201300276A (es) |
IL (3) | IL229380B (es) |
MA (1) | MA35180B1 (es) |
MX (1) | MX347019B (es) |
MY (1) | MY163736A (es) |
NI (1) | NI201300119A (es) |
PE (1) | PE20141018A1 (es) |
PH (1) | PH12017501368A1 (es) |
SG (2) | SG10201609729VA (es) |
TN (1) | TN2013000468A1 (es) |
TW (3) | TW201834687A (es) |
UA (1) | UA114401C2 (es) |
UY (1) | UY34077A (es) |
WO (1) | WO2012156455A1 (es) |
ZA (1) | ZA201309400B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
CN105814079B (zh) | 2013-08-30 | 2021-02-09 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
CN105837689B (zh) * | 2015-01-13 | 2020-06-19 | 博生吉安科细胞技术有限公司 | 抗cd19单克隆抗体及其制备方法 |
WO2016180941A1 (en) * | 2015-05-13 | 2016-11-17 | Sanofi | Liquid compositions for anti-cd19 antibody-drug conjugates |
EP3603672A1 (en) | 2015-05-26 | 2020-02-05 | MorphoSys AG | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
WO2017032679A1 (en) | 2015-08-21 | 2017-03-02 | Morphosys Ag | Combinations and uses thereof |
CN108601828B (zh) | 2015-09-17 | 2023-04-28 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
RS65120B1 (sr) | 2015-11-25 | 2024-02-29 | Immunogen Inc | Farmaceutske formulacije i postupci za njihovu upotrebu |
IL263103B2 (en) | 2016-05-30 | 2023-10-01 | Morphosys Ag | Methods for predicting the therapeutic benefit of anti-CD19 therapy in patients |
SG10201912369QA (en) | 2016-06-27 | 2020-02-27 | Morphosys Ag | Anti-cd19 antibody formulations |
RS62036B1 (sr) | 2016-10-28 | 2021-07-30 | Morphosys Ag | Kombinacija anti cd19 antitela sa bcl-2 inhibitorom i njihova upotreba |
WO2018183494A1 (en) * | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Cd19-targeting antibody-drug conjugates |
EP3612839A1 (en) * | 2017-04-20 | 2020-02-26 | ADC Therapeutics SA | Combination therapy |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
AU2018336520A1 (en) | 2017-09-21 | 2020-03-19 | WuXi Biologics Ireland Limited | Novel anti-CD19 antibodies |
CN111587125A (zh) | 2018-01-12 | 2020-08-25 | 伊缪诺金公司 | 抗体药物缀合、纯化和调配的方法 |
FI3958977T3 (fi) | 2019-04-26 | 2023-12-12 | Immunogen Inc | Kamptotesiinijohdannaisia |
JP2022532519A (ja) | 2019-05-03 | 2022-07-15 | モルフォシス・アーゲー | 限られた数のnk細胞を有する患者における抗cd19療法 |
US20210130460A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
EP4051710A1 (en) | 2019-10-31 | 2022-09-07 | MorphoSys AG | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells |
MX2022005123A (es) * | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
CN111303286B (zh) * | 2019-12-05 | 2022-05-20 | 常州费洛斯药业科技有限公司 | 一种anti-CD19的全人源抗体或抗体片段及其嵌合抗原受体和应用 |
CA3181827A1 (en) | 2020-06-22 | 2021-12-30 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint |
IL301865A (en) | 2020-10-06 | 2023-06-01 | Xencor Inc | Biomarkers, methods and preparations for the treatment of autoimmune disease, including systemic lupus erythematosus (SLE) |
WO2022117799A2 (en) | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
WO2024038115A1 (en) | 2022-08-17 | 2024-02-22 | Morphosys Ag | Therapy comprising anti-cd19 antibody and ezh2 modulators |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
EP3851126A1 (en) * | 2003-05-20 | 2021-07-21 | ImmunoGen, Inc. | Maytansinoid-cell-binding agent conjugates |
KR101456728B1 (ko) * | 2006-09-08 | 2014-10-31 | 메디뮨 엘엘씨 | 인간화 항-cd19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도 |
IL271761B (en) * | 2009-02-05 | 2022-09-01 | Immunogen Inc | (12as)-8-methoxy-9-benzyloxy-11,12,12a,13-tetrahydro-6h-indolo[2,1-c][1,4]benzodiazepine-6-one, 4-benzyloxy-5-methoxy -2-nitrobenzoic acid and a process for their preparation |
KR101725170B1 (ko) * | 2009-05-06 | 2017-04-10 | 바이오테스트 아게 | Cd138을 표적으로 하는 면역접합체의 용도 |
BR112012009250A2 (pt) * | 2009-10-21 | 2017-06-20 | Immunogen Inc | composição compreendendo conjugado anti-cd56-maitansinoide e uso da mesma |
EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
EP2550975A1 (en) * | 2011-07-29 | 2013-01-30 | Sanofi | Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab |
-
2011
- 2011-05-17 EP EP11290232A patent/EP2524929A1/en not_active Ceased
-
2012
- 2012-05-16 AU AU2012258254A patent/AU2012258254B2/en not_active Ceased
- 2012-05-16 AR ARP120101724A patent/AR086412A1/es unknown
- 2012-05-16 JP JP2014510798A patent/JP6050328B2/ja not_active Expired - Fee Related
- 2012-05-16 WO PCT/EP2012/059141 patent/WO2012156455A1/en active Application Filing
- 2012-05-16 EP EP12721529.1A patent/EP2710034A1/en not_active Withdrawn
- 2012-05-16 KR KR1020137033076A patent/KR20140043388A/ko active IP Right Grant
- 2012-05-16 CA CA2835738A patent/CA2835738A1/en not_active Abandoned
- 2012-05-16 UA UAA201314732A patent/UA114401C2/uk unknown
- 2012-05-16 EA EA201391714A patent/EA028574B1/ru not_active IP Right Cessation
- 2012-05-16 SG SG10201609729VA patent/SG10201609729VA/en unknown
- 2012-05-16 MX MX2013013455A patent/MX347019B/es active IP Right Grant
- 2012-05-16 CN CN201611022631.9A patent/CN107007840A/zh active Pending
- 2012-05-16 SG SG2013083407A patent/SG194894A1/en unknown
- 2012-05-16 US US14/117,806 patent/US9555126B2/en not_active Expired - Fee Related
- 2012-05-16 MY MYPI2013004057A patent/MY163736A/en unknown
- 2012-05-16 BR BR112013029330A patent/BR112013029330A8/pt not_active IP Right Cessation
- 2012-05-16 PE PE2013002503A patent/PE20141018A1/es not_active Application Discontinuation
- 2012-05-16 CN CN201280023918.7A patent/CN103547596A/zh active Pending
- 2012-05-17 TW TW107102069A patent/TW201834687A/zh unknown
- 2012-05-17 UY UY0001034077A patent/UY34077A/es not_active Application Discontinuation
- 2012-05-17 TW TW101117628A patent/TWI601537B/zh not_active IP Right Cessation
- 2012-05-17 TW TW105134320A patent/TW201726167A/zh unknown
-
2013
- 2013-11-11 IL IL229380A patent/IL229380B/en active IP Right Grant
- 2013-11-12 GT GT201300276A patent/GT201300276A/es unknown
- 2013-11-12 TN TNP2013000468A patent/TN2013000468A1/fr unknown
- 2013-11-12 NI NI201300119A patent/NI201300119A/es unknown
- 2013-11-12 DO DO2013000260A patent/DOP2013000260A/es unknown
- 2013-11-13 CR CR20130593A patent/CR20130593A/es unknown
- 2013-11-14 CL CL2013003272A patent/CL2013003272A1/es unknown
- 2013-12-12 ZA ZA2013/09400A patent/ZA201309400B/en unknown
- 2013-12-12 MA MA36558A patent/MA35180B1/fr unknown
- 2013-12-16 EC ECSP13013084 patent/ECSP13013084A/es unknown
- 2013-12-16 CO CO13293559A patent/CO6821893A2/es unknown
-
2016
- 2016-07-21 AU AU2016206317A patent/AU2016206317A1/en not_active Abandoned
- 2016-11-22 JP JP2016226407A patent/JP6181273B2/ja not_active Expired - Fee Related
- 2016-12-16 US US15/381,266 patent/US20170196988A1/en not_active Abandoned
-
2017
- 2017-07-18 JP JP2017138852A patent/JP2018021020A/ja active Pending
- 2017-07-28 PH PH12017501368A patent/PH12017501368A1/en unknown
-
2018
- 2018-02-12 IL IL257475A patent/IL257475A/en unknown
- 2018-03-01 AU AU2018201504A patent/AU2018201504A1/en not_active Abandoned
- 2018-12-16 IL IL263728A patent/IL263728A/en unknown
-
2019
- 2019-05-08 JP JP2019087962A patent/JP2019142961A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013003272A1 (es) | Métodos de tratamientos terapéuticos contra células b cd19 positivas a través de la administración del inmunoconjugado hub4-dm4 (sar3419); regimenes de administración; artículos manufacturados que contengan el inmunoconjugado | |
HK1254720A1 (zh) | 眼科治療 | |
DK2709667T3 (da) | Bio-orthogonal lægemiddelaktivering | |
EP2683291A4 (en) | PERSONAL DEVICE PORTABLE ON THE BODY WITH DIFFERENT PHYSICAL CONFIGURATIONS | |
BR112014006419A2 (pt) | métodos para tratar um paciente com câncer, kit e artigo | |
CU24159B1 (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
EP2838334A4 (en) | SEED TREATMENT DEVICE WITH IMPROVED FLUID APPLICATION | |
DK2760886T3 (da) | Immunocytokin-kombinationsterapi | |
FI20115876A0 (fi) | Yhdistelmähoito | |
EP2802302A4 (en) | APPLYING ENERGY FOR MEDICAL TREATMENTS | |
HUE046154T2 (hu) | A DIMS0-150 nukleotid alkalmazása a krónikus aktív fekélyes vastagbélgyulladás kezelésében | |
CO6801765A2 (es) | Isoxazolinas como agentes terapéuticos | |
HRP20180011T1 (hr) | Spojevi za uporabu u liječenju filariaza | |
IL228589A0 (en) | Medical Care | |
GB201114901D0 (en) | Vascular treatments | |
RS55092B1 (sr) | Upotreba 3-karboksi-n-etil-n,n-dimetilpropan-1-aminijum soli u lečenju kardiovaskularne bolesti | |
PL395785A1 (pl) | Zastosowanie medyczne N-etylo-3-amino-4-fenylo-5-okso-2,5-dihydro-1H-pirazolo-1-karbotioamidu | |
GB201115761D0 (en) | Therapeutic treatments | |
GB201115759D0 (en) | Therapeutic treatments | |
GB201214456D0 (en) | Therapeutic treatments | |
GB201214454D0 (en) | Therapeutic treatments | |
ES1076586Y (es) | Dispositivo de dilatacion del lobulo adaptable a pendientes | |
ZA201307614B (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease | |
ZA201306186B (en) | Treatment of disorders with altered vascular barrier function | |
UA22614S (uk) | Пляшка медична |